This e-learning course discusses the impact of TRIBE-2, Re-ARRANGE and FOxTROT data in colorectal cancer (CRC) on sequential clinical practice. Key clinical questions will be addressed, including;

  • Can we use a flexible dosing approach for regorafenib to improve the safety profile without affecting the efficacy in refractory metastatic colorectal cancer (mCRC)?
  • What is the best sequential therapy strategy in mCRC: a classic first and second line regimen or upfront higher regimen followed by the same regimen?
  • Is neoadjuvant chemotherapy effective in the treatment of CRC?

This course has been accredited by EACCME® for 1 ECMEC® (as detailed within the Introduction and Objectives below).